Innovative Cellular Therapeutics Holdings Ltd
SEC Form 4 insider trading activity
Innovative Cellular Therapeutics Holdings Ltd has filed 6 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2026. 6 of those filings fall inside the rolling window. Most recent filing: Jul 28, 2026.
On the most recent filing, Innovative Cellular Therapeutics Holdings Ltd is listed as 10% Owner at Lyell Immunopharma, Inc. Inside the rolling window, Innovative Cellular Therapeutics Holdings Ltd reported no open-market purchases and 2 open-market sales totaling $274 in LYEL. The largest disclosed transaction in the window is a sale of 10 LYEL shares on Jul 16, 2026, worth $137.
Companies traded
Other insiders at LYEL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$274
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Innovative Cellular Therapeutics Holdings Ltd made?
Innovative Cellular Therapeutics Holdings Ltd has filed 6 SEC Form 4 filings (6 transaction rows) across 1 company since 2026.
Which companies does Innovative Cellular Therapeutics Holdings Ltd trade?
Innovative Cellular Therapeutics Holdings Ltd has filed SEC Form 4 disclosures for 1 company, including LYEL.
When was Innovative Cellular Therapeutics Holdings Ltd's most recent SEC Form 4 filing?
Innovative Cellular Therapeutics Holdings Ltd's most recent SEC Form 4 filing on Tracefour is dated Jul 28, 2026.
What is Innovative Cellular Therapeutics Holdings Ltd's total buy and sell value in the current window?
Inside the rolling retention window, Innovative Cellular Therapeutics Holdings Ltd bought $0 and sold $274 based on SEC Form 4 filings.
What was Innovative Cellular Therapeutics Holdings Ltd's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10 LYEL shares on 2026-07-16, worth $137, per SEC Form 4 filings.